Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022.
Sara S KimJessie R ChungH Keipp TalbotCarlos G GrijalvaKaren J WernliErika KiniryEmily T MartinArnold S MontoEdward A BelongiaHuong Q McLeanManjusha GaglaniMufaddal MamawalaMary Patricia NowalkKrissy Moehling GeffelSara Y TartofAna FloreaJustin S LeeMark W TenfordeManish M PatelBrendan Flannerynull nullMeghan L BentzAlex BurginMark BurroughsMorgan L DavisDakota HowardKristine LacekJoseph C MaddenSarah NoblesJasmine PadillaMili ShethPublished in: Influenza and other respiratory viruses (2022)
In this adult population, three mRNA COVID-19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID-19 in the United States. These findings support the recommendation for a third mRNA COVID-19 vaccine dose.